---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-105453"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-10-01T11:57:57+00:00"
generated_at: "2026-10-12T14:15:53.094175+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nektar's rezpegaldesleukin shows durable hair regrowth in alopecia areata; Phase 3 ZENITH AA to start early 2027

## Summary
- Alopecia areata: SALT Score ≤20 response maintained in 75% (6/8) at 4 months off treatment and 63% (5/8) at 6 months; SALT ≤10 deepened from 7% at Week 52 to 19% off treatment.
- REZOLVE-AA: Week 36-52, 29% low dose (18 µg/kg) and 31% high dose (24 µg/kg) achieved new SALT ≤20 vs none on placebo; 850-patient Phase 3 ZENITH AA starts early 2027.
- Atopic dermatitis REZOLVE-AD: maintenance Q4W raised EASI-100 from 4% to 22%; Q12W from 9% to 18%; among prior responders, Q4W 6% to 30%, Q12W 14% to 27%.
- Third Phase 3 ZENITH AD study initiated in treatment-experienced atopic dermatitis; safety through 52 weeks favorable and consistent with prior profile.

## SEC filing metadata
- accession: 0001213900-26-105453
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-10-01T11:57:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/0001213900-26-105453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/ea0307306-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-105453
- JSON: https://secwatch.observer/filing/0001213900-26-105453.json
- Plain text: https://secwatch.observer/filing/0001213900-26-105453.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.